Yes, eczema is a chronic skin disorder. More specifically, it is an inflammatory condition rooted in a dysfunctional skin barrier and an overactive immune response. It affects roughly 20% of children and up to 10% of adults worldwide, making it one of the most common skin conditions. While it looks and feels like a surface-level problem, eczema involves deeper biological processes that distinguish it from a simple rash or dry skin.
What Makes Eczema a Skin Disorder
Eczema centers on the skin’s outermost protective layer, called the stratum corneum. In healthy skin, this layer acts like a sealed wall, keeping moisture in and irritants out. In people with eczema, that wall has gaps. The primary reason is a shortage of a protein called filaggrin, which helps build and maintain the skin barrier. Up to 10% of people carry genetic mutations that reduce or eliminate filaggrin production, and these mutations are one of the strongest known genetic risk factors for developing eczema.
Without enough filaggrin, the skin loses water more easily and becomes dry and cracked. Those cracks allow allergens, bacteria, and irritants from the environment to penetrate the skin. Once they get through, the immune system reacts, and that reaction is what produces the redness, swelling, and intense itch that define eczema. So while the visible symptoms are on the skin, the disorder involves both a structural defect in the skin barrier and an immune system that overresponds to what gets through it.
The Immune Response Behind the Itch
Once the compromised skin barrier lets foreign substances in, the immune system launches a specific type of inflammatory response. Immune cells release signaling molecules that recruit more inflammatory cells to the skin, creating a cycle of inflammation that sustains itself. These same signals directly stimulate nerve fibers in the skin, which is why eczema itch is so persistent and doesn’t respond well to standard antihistamines. The itch-scratch cycle then causes further physical damage to the already weakened barrier, letting in more irritants and triggering more inflammation.
This self-reinforcing loop is why eczema tends to be chronic and relapsing rather than something that clears up on its own. It also explains why treatment targets both the skin barrier (through moisturizers) and the immune response (through anti-inflammatory therapies).
Types of Eczema
Eczema is actually an umbrella term covering several related conditions:
- Atopic dermatitis is the most common form and the one most people mean when they say “eczema.” It typically begins in childhood and is linked to a family history of allergies and asthma.
- Contact dermatitis occurs when the skin reacts to a specific substance, like nickel, fragrances, or latex. It often causes burning alongside itching.
- Dyshidrotic eczema produces small, intensely itchy blisters on the hands and feet.
- Nummular eczema appears as coin-shaped patches, often after a skin injury.
- Seborrheic dermatitis targets oil-rich areas like the scalp, face, and chest.
- Neurodermatitis involves thick, scaly patches that develop from repeated scratching of a specific area.
Each type has distinct triggers and patterns, but they all share the core features of inflammation, barrier disruption, and itch.
Genetics and Family Risk
Eczema runs in families. Children with one parent who has eczema are two to three times more likely to develop it themselves, regardless of whether the affected parent is the mother or father. The filaggrin gene mutations mentioned earlier are a major part of this inherited risk, but they aren’t the whole story. Many people with eczema have normal filaggrin genes, meaning other genetic and environmental factors also play a role.
A family history of asthma, hay fever, or food allergies also increases a child’s likelihood of developing eczema, since these conditions share overlapping immune pathways.
How Eczema Connects to Asthma and Allergies
Eczema is often the first step in a progression that doctors call the “atopic march.” About one in three children with eczema goes on to develop asthma later in childhood. The risk scales with severity: roughly 70% of children with severe eczema eventually develop asthma, compared to about 8% of children in the general population. Children with eczema also have about a threefold increased chance of developing hay fever.
The connection likely starts at the skin. When a leaky skin barrier allows allergens to enter the body through the skin rather than through the gut or airways, it can prime the immune system to react to those substances elsewhere. Food allergy affects about 35% of children with eczema, and early food sensitization combined with filaggrin mutations increases the risk of both persistent eczema and later asthma. Nearly half of children with eczema in infancy will still have eczema, asthma, or hay fever by the time they reach their preteen years.
What Triggers Flares
Even when eczema is well controlled, certain environmental factors can set off a flare. Common triggers include high indoor humidity, synthetic bedding materials, and electric space heaters. Air pollution, particularly in urban areas, has been increasingly recognized as a contributor to both the onset and severity of eczema symptoms. Wool, solvents, and sweat are direct skin irritants that can provoke a reaction. Emotional stress, certain foods, and seasonal weather changes are also well-documented triggers.
Interestingly, households that vacuum regularly show lower rates of eczema in children, likely because reducing dust mite exposure limits one source of allergen penetration through the compromised skin barrier. Identifying and minimizing your personal triggers is one of the most effective long-term management strategies.
How Eczema Is Diagnosed
There is no single blood test or biopsy for eczema. Diagnosis is clinical, based on a combination of visible signs and patient history. Dermatologists typically look for at least three of four major features: persistent itching, a characteristic rash pattern (on the inner elbows and behind the knees in adults, or on the face and outer limbs in infants), a chronic or relapsing course, and a personal or family history of eczema, asthma, or hay fever.
Supporting signs include very dry skin, darkening under the eyes, extra skin folds on the palms, small bumps on the upper arms (plugged hair follicles), and flares triggered by specific irritants or emotional stress. The pattern of where the rash appears and how it behaves over time is usually enough for a confident diagnosis.
Treatment Approaches
Eczema management follows a layered approach. The foundation is consistent moisturizing to repair and support the skin barrier. This alone can reduce flare frequency for many people with mild eczema. Bathing practices matter too: lukewarm water, gentle cleansers, and applying moisturizer within minutes of drying off help lock in hydration.
When moisturizers aren’t enough, prescription anti-inflammatory creams are the next step. These include corticosteroid creams of varying strengths and newer non-steroid options that target specific inflammatory pathways in the skin. The American Academy of Dermatology’s most recent guidelines, updated in 2025, strongly recommend several newer topical therapies alongside traditional options, giving patients and doctors more choices for long-term control without relying on steroids.
For moderate to severe eczema that doesn’t respond to topical treatment, injectable medications that block the specific immune signals driving eczema inflammation have transformed care in recent years. These target the overactive immune pathways at their source and can dramatically reduce symptoms. Oral medications that interrupt the same signaling pathways are also available. Notably, current guidelines recommend against using oral steroids for eczema because the flare that follows when you stop them is often worse than the original episode.
Light therapy, which exposes the skin to controlled amounts of ultraviolet light, is another option for widespread eczema that hasn’t responded to creams alone. Most people with eczema find that a combination of barrier repair, trigger avoidance, and targeted anti-inflammatory treatment keeps the condition manageable, though it rarely disappears entirely in adults who had it as children.